Sanofetil Special Precautions

In some cases PRCA was found to be reversible with dose reduction cessation of SANOFETIL therapy. In transplant patients however reduced immunosuppression may place the graft at risk.
Increased risk of developing lymphomas and other malignancies, particularly of the skin (see Adverse Reactions).
Vaccinations maybe less effective and the use of live attenuated vaccines should be avoided (see Interactions). Influenza vaccination may be of value.
Because SANOFETIL is an inosine monophosphate dehydrogenase (IMPDH) inhibitor, on theoretical grounds it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
It is recommended that SANOFETIL should not be administered concomitantly with azathioprine because both have the potential to cause bone marrow suppression and such concomitant administration has not been studied.
Administration of doses greater than 1 g b.i.d. to renal patients with severe chronic renal impairment should be avoided (see Special dosage instructions under Dosage & Administration).
SANOFETIL should be avoided in pregnant woman unless the potential benefit outweighs the potential risk to the fetus.